Previous 10 | Next 10 |
IQVIA has the potential to outperform the market in a higher inflation environment. Significant growth potential with projected 17.72% FCF and 11.68% EBIT CAGR over the next 5 years. Decentralized clinical trials, the emergence of virtual trials, blockchain technologies, AI and ML...
IQVIA Holdings (NYSE:IQV) is trading higher for the third straight session on Friday after Piper Sandler upgraded the contract research organization to Overweight from Neutral, refuting the concerns over public equity financing in early-stage biopharma companies. “Investor concerns abo...
BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...
Image source: The Motley Fool. IQVIA Holdings, Inc. (NYSE: IQV) Q1 2022 Earnings Call Apr 27, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: IQVIA Holdings, Inc. (IQV) Q1 2022 Earnings Call Transcript
IQVIA Holdings Inc. (IQV) Q1 2022 Earnings Conference Call April 27, 2022, 09:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Corporate Communications Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chie...
IQVIA press release (NYSE:IQV): Q1 Non-GAAP EPS of $2.47 beats by $0.05. Revenue of $3.57B (+4.7% Y/Y) beats by $30M. Full-year 2022 revenue guidance range updated for foreign exchange and the Ukraine/Russia crisis Full-year 2022 guidance ranges reaffirmed for Adjusted EBITDA and Ad...
Revenue of $3,568 million increased 4.7 percent year-over-year on a reported basis and 6.8 percent at constant currency GAAP Net Income of $325 million grew 53.3 percent year-over-year Adjusted EBITDA of $812 million grew 9.1 percent year-over-year GAAP Dilut...
IQVIA (NYSE:IQV) is scheduled to announce Q1 earnings results on Tuesday, April 27th, before market close. The consensus EPS Estimate is $2.42 (+11.0% Y/Y) and the consensus Revenue Estimate is $3.54B (+3.8% Y/Y). Over the last 2 years, IQV has beaten EPS estimates 100% of the time and has be...
The shares of the Medpace Holdings (NASDAQ:MEDP) have reached a 52-week low on Tuesday after the contract research organization set the 2022 outlook unchanged despite its 1Q 2022 financials that stood above Street forecasts. The peers in the subsector, including ICON (ICLR), IQVIA Holdin...
Wells Fargo has downgraded life sciences company Thermo Fisher Scientific (NYSE:TMO) to underweight and lowered the price target from $605 to $525, citing an expensive valuation and "material headwinds for the stock ahead". Thermo Fisher (TMO) is trading -4.37% currently and -1...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...